Pauline Funchain
Overview
Explore the profile of Pauline Funchain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribaudo I, Arbesman M, Ni Y, Isaacs J, Kennedy L, Ko J, et al.
Pigment Cell Melanoma Res
. 2025 Mar;
38(2):e70007.
PMID: 40045179
Mucosal melanomas (MM) are rare but aggressive malignancies, comprising only 1.3% of all melanoma diagnoses, with a poor 5-year survival rate below 20%. MM lacks identifiable risk factors, presents with...
2.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
3.
Savage D, Switzer B, Parikh R, Song J, Stanek C, Arbesman J, et al.
Melanoma Manag
. 2025 Jan;
11(1):2424708.
PMID: 39869444
This study determined the characteristics of patients with early-stage melanoma (IA-IIA) who later had stage IV recurrence. We retrospectively examined 880 melanoma patients and identified those who progressed to stage...
4.
Shen A, Arbesman M, Lodha R, Rayman P, Gastman B, Ko J, et al.
J Invest Dermatol
. 2025 Jan;
PMID: 39814198
No abstract available.
5.
Reynolds K, Funchain P
Lancet Oncol
. 2024 Nov;
25(12):1519-1521.
PMID: 39551066
No abstract available.
6.
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400375.
PMID: 39509669
Purpose: Patients with stage II and III cutaneous primary melanoma vary considerably in their risk of melanoma-related death. We explore the ability of methylation profiling to distinguish primary melanoma methylation...
7.
Braghieri L, Gharaibeh A, Nkashama L, Abushouk A, Abushawer O, Mehdizadeh-Shrifi A, et al.
ESC Heart Fail
. 2024 Nov;
PMID: 39482568
Aims: Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI-related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it...
8.
Dima D, Lopetegui-Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, et al.
Cancer Med
. 2024 Jul;
13(12):e7257.
PMID: 39031560
Background: Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real-world outcomes are limited. In addition, a significant proportion...
9.
Phoon Y, Lopes J, Pfannenstiel L, Diaz-Montero C, Tian Y, Ernstoff M, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604813
Background: Despite recent advances in immunotherapy, a substantial population of late-stage melanoma patients still fail to achieve sustained clinical benefit. Lack of translational preclinical models continues to be a major...
10.
Funchain P, Ni Y, Heald B, Bungo B, Arbesman M, Behera T, et al.
J Am Acad Dermatol
. 2024 Mar;
91(2):265-272.
PMID: 38513832
Background: Prior studies have estimated a small number of individuals with melanoma (2%-2.5%) have germline cancer predisposition, yet a recent twin study suggested melanoma has the highest hereditability among cancers....